Skip to Content
Merck
  • Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells.

Quantitative site- and structure-specific N-glycoproteomics characterization of differential N-glycosylation in MCF-7/ADR cancer stem cells.

Clinical proteomics (2020-02-12)
Feifei Xu, Yue Wang, Kaijie Xiao, Yechen Hu, Zhixin Tian, Yun Chen
ABSTRACT

Cancer stem cells (CSCs) are reported to be responsible for tumor initiation, progression, metastasis, and therapy resistance where P-glycoprotein (P-gp) as well as other glycoproteins are involved. Identification of these glycoprotein markers is critical for understanding the resistance mechanism and developing therapeutics. In this study, we report our comparative and quantitative site- and structure-specific N-glycoproteomics study of MCF-7/ADR cancer stem cells (CSCs) vs. MCF-7/ADR cells. With zic-HILIC enrichment, isotopic diethyl labeling, RPLC-MS/MS (HCD) analysis and GPSeeker DB search, differentially expressed N-glycosylation was quantitatively characterized at the intact N-glycopeptide level. 4016 intact N-glycopeptides were identified with spectrum-level FDR ≤ 1%. With the criteria of ≥ 1.5 fold change and p value < 0.05, 247 intact N-glycopeptides were found differentially expressed in MCF-7/ADR CSCs as putative markers. Raw data are available via ProteomeXchange with identifier PXD013836. Quantitative site- and structure-specific N-glycoproteomics characterization may help illustrate the cell stemness property.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2,2,2-Trifluoroethanol, ReagentPlus®, ≥99%
Sigma-Aldrich
Indole-3-acetic acid sodium salt, BioReagent, suitable for plant cell culture, ≥98%